Brainsway Ltd. (TASE:BRIN) reports success in a clinical trial of its Deep TMS (transcanial magnetic stimulation) treatment of Parkinson's disease.
The two-year trial of patients at Sheba Medical Center Tel Hashomer, near Tel Aviv, found that magnetic stimulation of prefrontal and motor cortex was safe and effective in significantly improving motor function of Parkinson's patients.
47 Parkinson's patients participated in three studies. The patients in the various groups received 12 treatments over a 30-day period, and were examined with standard motor function tests after one, 10, 30, and 60 days. The researchers said that the successful treatment indicated the importance of conducting a multi-center double-blind trial using the same parameters found to be the most effective compared with the control group.
Brainsway CEO Uzi Sofer said, "This was a long study, and we insisted on seeking suitable and optimal parameters for treating this population. This is unquestionably good news for patients with Parkinson's disease, who can receive non-invasive treatment for their disease, a treatment that we hope will be approved in the future. We will use these results to apply for EU CE Mark certification, and we will obviously move quickly to a multi-center study for US Food and Drug Administration (FDA) certification."
Brainsway's share price jumped 7.6% in morning trading on the announcement, but fell back to 3.9% by mid-afternoon to NIS 8.97, giving a market cap of NIS 410 million.
Published by Globes [online], Israel business news - www.globes-online.com - on March 1, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011